Plasmapheresis, Anti-ACE2 and Anti-FcγRII Monoclonal Antibodies: A Possible Treatment for Severe Cases of COVID-19
Amin Sedokani,1 Sadegh Feizollahzadeh2 1Cardiology Department, Medical Faculty, Urmia University of Medical Sciences, Urmia, Iran; 2Medical Immunology, Laboratory Sciences, School of Allied Medical Sciences, Urmia University of Medical Sciences, Urmia, IranCorrespondence: Amin SedokaniCardiology Dep...
Main Authors: | Sedokani A, Feizollahzadeh S |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2020-07-01
|
Series: | Drug Design, Development and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/plasmapheresis-anti-ace2-and-anti-fcgammarii-monoclonal-antibodies-a-p-peer-reviewed-article-DDDT |
Similar Items
-
TRADITIONAL AND CASCADE PLASMAPHERESIS IN ANTIBODY TITERS’ REDUCTION IN RENAL TRANSPLANT RECIPIENTS
by: A.V. Vatazin, et al.
Published: (2014-05-01) -
Realizing the Potential of Anti-SARS-CoV-2 Monoclonal Antibodies for COVID-19 Management
by: Gandhi, R.T, et al.
Published: (2022) -
Monoclonal antibody as a potential anti-COVID-19
by: Leila Jahanshahlu, et al.
Published: (2020-09-01) -
Production and characterization of monoclonal antibodies anti fragment Fc of bovine IgG
by: Tânia Regina Penha, et al.
Published: (2010-02-01) -
FEATURES OF PLASMAPHERESIS IN THE TREATMENT OF GRAFT REJECTION AFTER KIDNEY TRANSPLANTATION
by: A. V. Vatazin, et al.
Published: (2015-10-01)